VYNE Therapeutics Email Formats

Biotechnology Research • Bridgewater, New Jersey, United States • 51-100 Employees

VYNE Therapeutics Email Formats

VYNE Therapeutics uses 1 email format. The most common is {first name}.{last name} (e.g., john.doe@vynetx.com), used 100% of the time.

Format	Example	Percentage
{first name}.{last name}	john.doe@vynetx.com	100%

Key Contacts at VYNE Therapeutics

Helen Cocuzza

Director, Regulatory Affairs

Theresa Lyle Meier

Director, Sec Reporting

Tami Winitz-Yehezkel

Associate Director Ip And Legal Contracts Nasdaq: Vyne A/K/A Foamix Pharmaceuticals Ltd.

David Domzalski

Chief Executive Officer

Company overview

Headquarters	520 U.S. Highway 22, Suite 204, Bridgewater, NJ 08807, US
Phone number	+18007757936
Websites	vynetherapeutics.com menlotx.com
NAICS	541714
SIC	873
Keywords	Skin, Dermatology, Immuno-Inflammatory
Founded	2003
Employees	51-100
Socials

About VYNE Therapeutics

VYNE Therapeutics is a clinical-stage biopharmaceutical company focused on developing differentiated therapies to treat chronic inflammatory and immunological (I&I) conditions with high unmet need. Led by a proven and resourceful team of drug developers, VYNE is applying scientific innovation to advance novel therapies that have the potential to improve the lives of millions of people afflicted by autoimmune diseases. The catalyst of the company’s differentiated approach is its proprietary InhiBET™ Platform that potentially unlocks a promising new drug target for improving the treatment of challenging I&I diseases with significant unmet medical needs. BETs are a family of proteins that are believed to play a causal role in the regulation of inflammatory genes that are implicated in numerous diseases. VYNE has done the first formative work in applying BET inhibition to the treatment of autoimmune disease. The company’s leadership is demonstrated in clinical development, where VYNE is building a superior body of evidence that informs the advancement of its two lead product candidates: VYN201 for the treatment of vitiligo; and VYN202, a highly potent and selective BET inhibitor that offers promise across a broad array of chronic autoimmune indications. To learn more about us and our pipeline, visit vynetherapeutics.com. Read our Social Media Guidelines here: https://vynetherapeutics.com/social-media-guidelines/.

Employees by Management Level

Total employees: 51-100

Seniority

Employees

Director

Entry

C-Suite

Employees by Department

VYNE Therapeutics has 9 employees across 6 departments.

Departments

Number of employees

Funding Data

VYNE Therapeutics has never raised funding before.

VYNE Therapeutics Tech Stack

Discover the technologies and tools that power VYNE Therapeutics's digital infrastructure, from frameworks to analytics platforms.

Modernizr

JavaScript libraries

jQuery UI

JavaScript libraries

jQuery Migrate

JavaScript libraries

Cloudflare

CDN

Twitter Emoji

Font scripts

Genesis theme

WordPress themes

jQuery

JavaScript libraries

SVG Support

WordPress plugins

HTTP/3

Miscellaneous

PHP

Programming languages

WordPress

Blogs

Google Analytics

Analytics

Frequently asked questions

VYNE Therapeutics is located in Bridgewater, New Jersey, US.

You can reach VYNE Therapeutics at +18007757936.

VYNE Therapeutics was founded in 2003, making it 23 years old. The company has established itself as a significant player in its industry over this time.

VYNE Therapeutics has approximately 51-100 employees. The company continues to grow its workforce to support its business operations and expansion.

Key Contacts at VYNE Therapeutics

Helen Cocuzza

Director, Regulatory Affairs

Theresa Lyle Meier

Director, Sec Reporting

Tami Winitz-Yehezkel

Associate Director Ip And Legal Contracts Nasdaq: Vyne A/K/A Foamix Pharmaceuticals Ltd.

David Domzalski

Chief Executive Officer

4.8

40,000 users